ReviewFrontiers in medicine2026
Artificial intelligence in chronic and autoimmune pancreatitis: diagnosis, prognosis, and personalized management.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic pancreatitis (CP) and autoimmune pancreatitis (AIP) have overlapping clinical and imaging features with pancreatic ductal adenocarcinoma (PDAC), resulting in frequent misdiagnosis and improper clinical treatment, and conventional diagnostic methods are subject to subjective factors, low accuracy and sampling errors. A review of the paradigm shift brought about by artificial intelligence (AI) in the diagnosis, prognosis and individualized management of CP and AIP. Based on AI, including deep learning and radiomics, has achieved a high-precision differential diagnosis and severity grading of CP and AIP by analyzing endoscopic ultrasound, CT, MRI and other imaging modalities, and integrates multi-source clinical, serological and omics data to further improve diagnostic efficiency. AI-powered digital pathology has realized quantitative histological analysis, and prognosis AI models can help predict complications such as exocrine pancreatic insufficiency and treatment non-adherence to support early intervention. In addition, we also address the current problems of AI in clinical translation, such as model overfitting and the "black box" issue, and indicate that prospective multicentre studies, explainable AI, and multimodal data integration will be the primary directions for future research, thereby promoting the development of precision medicine in pancreatology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.